Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis

Area of Science:

• Cardiovascular Biology
• Extracellular Matrix Remodeling
• Enzyme Function in Disease

Background:

• Matrix-degrading metalloproteinases (MMPs) are crucial for atherosclerotic plaque development, including inflammatory cell infiltration, smooth muscle cell migration, and angiogenesis.
• MMP activity contributes to plaque instability and rupture, leading to clinical events such as myocardial infarction and stroke.
• MMPs degrade extracellular matrix components, and their activity is tightly regulated in healthy vessels but dysregulated in atherosclerosis.

Purpose of the Study:

• To investigate the role of MMPs in the pathogenesis of atherosclerosis.
• To explore the potential of MMP inhibition or restoring MMP:TIMP balance as a therapeutic strategy for atherosclerosis.

Main Methods:

• Review of existing literature on MMP activity in atherosclerosis.
• Analysis of mechanisms leading to increased MMP activity during plaque development.
• Evaluation of recent studies on synthetic MMP inhibitors and gene therapy.

Main Results:

• Increased MMP activity, driven by cytokine/growth factor signaling, zymogen activation, and MMP:TIMP imbalance, promotes atherosclerotic plaque progression and instability.
• Degradation of the extracellular matrix by MMPs is a key factor in plaque rupture and subsequent clinical events.
• Synthetic MMP inhibitors and gene therapy show promise in preclinical studies.

Conclusions:

• Targeting MMPs or re-establishing the MMP:TIMP balance represents a potential therapeutic avenue for managing atherosclerosis and its complications.
• Further research into MMP inhibition strategies is warranted for the treatment of cardiovascular diseases.